Is Nivolumab an O drug?

Nivolumab (Nivolumab) is sold under the trade name Opdivo after its launch. It is also sold under the name Opdivo in China. It is also called O drug probably because of its English name. It is the first monoclonal antibody drug targeting PD-1 approved in China, and it is also the first immuno-oncology drug in China for the treatment of advanced gastric cancer.

Nivolumab has been approved for many cancer types and stages, in some cases as monotherapy and in some cases in combination with another immunotherapyipilimumab. Nivolumab is approved for melanoma, lung cancer, mesothelioma, kidney cancer, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, bladder and urethra (urothelial cell) cancer, colorectal cancer (MSI-H/dMMR), liver cancer, esophageal cancer, and gastric cancer. Nivolumab is a liquid that is given intravenously (into a vein) over 30 minutes by a doctor or nurse at a hospital or medical facility. When nivolumab is used alone, it is usually administered every 2 or 4 weeks. When nivolumab is given with ipilimumab or other chemotherapy drugs, it is usually given every 2, 3, or 4 weeks.

The generic drug Nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around RMB 4,000. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.